

Role of $\kappa \rightarrow \lambda$ light-chain constant-domain switch in the structure and functionality of A17 reactibody

Natalia Ponomarenko,^{a,‡}
Spyros D. Chatziefthimiou,^{b,‡}
Inna Kurkova,^a Yuliana
Mokrushina,^{a,‡} Anastasiya
Stepanova,^a Ivan Smirnov,^a
Marat Avakyan,^a Tatyana Bobik,^a
Azad Mamedov,^a Vladimir
Mitkevich,^c Alexey Belogurov
Jr.,^{a,d} Olga S. Fedorova,^e Michael
Dubina,^f Andrey Golovin,^g
Victor Lamzin,^b Alain Friboulet,^h
Alexander A. Makarov,^c Matthias
Wilmanns^b and Alexander
Gabibov^{a,d,g,*}

^aShemyakin–Ovchinnikov Institute of
Bioorganic Chemistry, Russian Academy of
Sciences, ul. Miklukho-Maklaya 16/10,
Moscow 117871, Russian Federation,

^bEuropean Molecular Biology Laboratory,
Hamburg Unit, c/o DESY, Notkestrasse 85,
22603 Hamburg, Germany, ^cEngelhardt Institute
of Molecular Biology, Russian Academy of
Sciences, Moscow 119991, Russian Federation,

^dInstitute of Gene Biology, Moscow 117334,
Russian Federation, ^eInstitute of Chemical
Biology and Fundamental Medicine, Siberian
Branch, Russian Academy of Sciences,

Novosibirsk 630090, Russian Federation,
^fSt Petersburg Academic University,
St Petersburg 194021, Russian Federation,

^gLomonosov Moscow State University,
Moscow 119991, Russian Federation, and

^hUniversité de Technologie de Compiègne,
Unité Mixte de Recherche 6022, Centre
National de la Recherche Scientifique,
60205 Compiègne, France

‡ These authors contributed equally to this
study.

Correspondence e-mail: gabibov@mx.ibch.ru

The engineering of catalytic function in antibodies requires precise information on their structure. Here, results are presented that show how the antibody domain structure affects its functionality. The previously designed organophosphate-metabolizing reactibody A17 has been re-engineered by replacing its constant κ light chain by the λ chain (A17 λ), and the X-ray structure of A17 λ has been determined at 1.95 Å resolution. It was found that compared with A17 κ the active centre of A17 λ is displaced, stabilized and made more rigid owing to interdomain interactions involving the CDR loops from the V_L and V_H domains. These V_L/V_H domains also have lower mobility, as deduced from the atomic displacement parameters of the crystal structure. The antibody elbow angle is decreased to 126° compared with 138° in A17 κ . These structural differences account for the subtle changes in catalytic efficiency and thermodynamic parameters determined with two organophosphate ligands, as well as in the affinity for peptide substrates selected from a combinatorial cyclic peptide library, between the A17 κ and A17 λ variants. The data presented will be of interest and relevance to researchers dealing with the design of antibodies with tailor-made functions.

1. Introduction

Exquisite specificity and high binding affinity, the hallmarks of the antibody (Ab) response, make Abs excellent tools for biotechnology and biomedical applications. During the past decade, achievements in the field of Ab engineering have markedly expanded the range of these applications. A number of engineering strategies have been applied to modify the functionality of therapeutic monoclonal Abs according to the requirements of the particular biological mechanism to be treated (Kaneko & Niwa, 2011; Klohn *et al.*, 2013; Lu *et al.*, 2012; Vincent & Zurini, 2012). The development of methods for the humanization and functional expression of Abs and their fragments, together with the emergence of powerful techniques for screening combinatorial libraries and the expansion of structure–function databases aided by refined X-ray analysis, has opened unlimited opportunities for the engineering of Abs with tailor-made properties for specific applications. X-ray crystal structure analysis has played a crucial role in creating novel artificial biocatalysts and engineered Abs (Ekiert *et al.*, 2012; Golinelli-Pimpaneau *et al.*, 2000; Guenaga & Wyatt, 2012; Privett *et al.*, 2012; Turner *et al.*, 2002; Zheng *et al.*, 2004).

Antibody recognition of protein antigens is predominantly mediated by four to six complementarity-determining regions (CDRs), which are variable loops at the tip of each antigen-binding fragment (Fab). Fabs are composed of two

Received 19 April 2013

Accepted 27 November 2013

PDB reference: A17 λ , 3z14

polypeptide chains: heavy (H) and light (L). Each chain is folded into two distinct immunoglobulin (Ig) domains, the N-terminal variable domain (V_H or V_L) and the C-terminal constant domain (C_{H1} or C_L), with the amino-acid residues linking V_L to C_L and V_H to C_{H1} called the switch residues (J fragment, framework 4). The elbow angle, or elbow bend, defined as the angle between the pseudo-twofold axes relating V_L to V_H and C_L to C_{H1} , is a highly variable parameter in antibodies, and its role in the antigen-binding capacity has been speculated on (Huber *et al.*, 1976; Landolfi *et al.*, 2001). It is still unknown how far the changes that a hapten induces in an Ab structure can extend. An analysis of Protein Data Bank (PDB) depositions has shown that in some cases significant differences exist between the elbow angles of liganded and unliganded Fabs (Stanfield, Zemla *et al.*, 2006; Stanfield, Gorny *et al.*, 2006). Dramatic changes in the domain structure of NC6.8 (an Ab directed against the compound NC174) caused by small ligand binding were revealed by X-ray structure analysis followed by various molecular-dynamics simulations (Guddat *et al.*, 1994, 1995; Sotriffer *et al.*, 2000). In particular, the elbow angle was shown to change by more than 30° . Mammalian Abs have two types of light chains, κ and λ , which are encoded by different chromosome loci. In general, λ -chain Abs have a less rigid conformation than κ -chain Abs, with the difference being reflected in the values of the elbow angle: about 195° in the former *versus* 125° in the latter (Stanfield, Zemla *et al.*, 2006). The apparent hyperflexibility of λ -chain Fabs may be owing to an insertion in their switch region, which usually consists of a glycine residue and hence can also provide more conformational freedom for their molecules.

Catalytic function is one of the most sophisticated features of Abs. Recently, the novel 'reactibody' approach has been developed, which is based on the chemical selection of bio-

catalysts from a human semisynthetic Ab variable-fragment library followed by eukaryotic expression in a full-length Ab. This approach has been used to produce a novel organophosphate-metabolizing biocatalyst named the A17 reactibody (Reshetnyak *et al.*, 2007; Smirnov *et al.*, 2011). An important task is to develop effective antidotes against very toxic organophosphate compounds, including nerve agents and pesticides. Organophosphate poisoning is a serious clinical problem in rural regions of the developing world, causing the deaths of 200 000 people per year (Eddleston *et al.*, 2008). It has been shown that the A17 reactibody is capable of irreversibly binding phosphonate X (Fig. 1*a*) and hydrolyzing the organophosphate pesticide paraoxon (Fig. 1*b*) by covalent catalysis with rate-limiting dephosphorylation. The crystal structures of unmodified and phosphorylated Fabs of A17 have previously been solved at 1.5 and 1.36 Å resolution, respectively. Structural analysis combined with kinetic studies has provided an insight into certain mechanistic features of the reaction catalyzed by A17 (Smirnov *et al.*, 2011). In particular, the catalytic Tyr-L37 in this reactibody proved to be located in a deep active-site cavity, which is not typical of Abs in general. Some differences were observed in the catalytic efficiency of full-length A17 or its Fab fragment compared with its parent single-chain variable-fragment (scFv) molecule, which were possibly owing to structural stabilization of the active centre by additional constant domains. The full-length A17 reactibody contained an artificial light chain in which the λV_L domain was fused to κC_L through the κ switch region (Fig. 1*c*), which possibly affected the functionality of the Ab. In the case of catalytic Abs, in which the active centre should have a rigid and precise structure to accomplish the catalytic function, cross-domain interaction effects can be extremely important. It has been shown that a change of the heavy-chain isotype (Sapparapu *et al.*, 2012) or Ab expression in the scFv format




Figure 1

Chemical compounds and antibody chains used in this study. (a) $R = H$, *p*-nitrophenyl 8-methyl-8-azabicyclo[3.2.1]octylphenylphosphonate (phosphonate X); $R = \text{biotin}$, biotinylated phosphonate X (BtX). (b) *O,O*-Diethyl *O*-(4-nitrophenyl)phosphate (paraoxon). (c) Amino-acid sequences of A17 κ and λ light chains and the heavy chain. Residues are numbered using the Kabat system (superlinear) and sequential numbering (interlinear). Frameworks (FR1–FR4) are underlined; switch residues of the J segment are designated as FR4 according to Kabat; CDRs are coloured magenta; constant domains κC_L , λC_L and C_{H1} are coloured green, yellow and blue, respectively.

(Ponomarenko *et al.*, 2007) affects the catalytic activity or substrate specificity of Abs. It was reasonable to assume that the $\kappa \rightarrow \lambda$ switch would change the architecture of the binding pocket of the Ab molecule. To study the effects of such a switch, we produced a functionally active catalytic Ab with the constant λ light chain, thereby reconstructing the natural Ab structure.

In this study, we present data on the effect of a $\kappa \rightarrow \lambda$ light-chain switch on the structure and function of the A17 reactibody. The available high-resolution structural data allowed us to trace the changes caused by this switch in the active centre and antigen-binding site, and to observe how the interdomain interactions of the CDR loops narrow the cavity entrance, thereby forming a more rigid structure. A comparative structural analysis of the A17 λ and A17 κ variants showed that the $\kappa \rightarrow \lambda$ switch results in a decrease in the Ab elbow angle, in contrast to previously published data. It was somewhat unexpected that A17 λ proved to have a rigid structure compared with A17 κ , with its catalytic activity and affinity changing only slightly despite major structural modifications. Hopefully, the data presented below will contribute to the advancement of research on the design of antibodies with tailor-made functions.

2. Materials and methods

2.1. Protein expression and purification

Recombinant FabA17 containing κ or λ light-chain constant regions was produced in the methylotrophic yeast *Pichia pastoris* GS115 using the modified expression vector pPICZ α /Jk1 (Zakharov *et al.*, 2011) based on pPICZ α A (Invitrogen, USA) (Supplementary Fig. S1¹).

Expression constructs for HC_H (human Ab heavy chain containing the C_{H1} constant domain with hinge region) and A17 κ light chain (Zakharov *et al.*, 2011) and the constant region of human λ 2 light chain with the J2 (joining) segment (Gabibov *et al.*, 2011) were prepared as described in the respective studies. To construct pPICZ α A/J λ 2, the PCR-amplified DNA fragment corresponding to J2 λ 2 was digested with *Kpn*I and *Sac*II and ligated into pPICZ α /Jk1 at the appropriate restriction sites. V_LA17 was amplified by PCR, digested with *Bsp*MI and *Spe*I, and cloned into pPICZ α /J λ 2 at the *Bsm*BI and *Avr*II restriction sites. All constructs were verified by DNA sequencing.

Procedures of electrocompetent cell preparation, electroporation of *P. pastoris* GS115 cells, Mut⁺ or Mut^s phenotype determination and selection on zeocin followed Invitrogen protocols. Analytical or large-scale expression of recombinant FabA17 was performed in cultures of BMGY and BMMY media according to the Invitrogen protocol. Methanol was added every 24 h after induction (up to 0.5%).

The culture medium was concentrated by ultrafiltration, equilibrated with 50 mM sodium phosphate buffer pH 8.0 containing 300 mM NaCl and purified on a Talon resin column

Table 1

Data-collection and refinement statistics.

Data-collection statistics	
Source	MX beamline P14, PETRA III, EMBL/DESY
No. of images	380
Oscillation range (°)	0.25
Space group	<i>P</i> ₄ ₁ ₂ ₁ ²
Unit-cell parameters (Å)	<i>a</i> = <i>b</i> = 60.63, <i>c</i> = 279.64
Wavelength (Å)	1.2234
Resolution (Å)	25.0–1.95 (2.06–1.95)
<i>R</i> _{merge} (%)	9.6 (85.4)
<i>R</i> _{r.i.m.} (%)	10.4 (92.0)
<i>R</i> _{p.i.m.} (%)	3.8 (33.9)
CC _{1/2}	99.7 (79.3)
<i>I</i> / <i>σ</i> (<i>I</i>)	15.6 (2.7)
Completeness (%)	99.9 (100)
Multiplicity	7.3 (7.3)
Estimated <i>B</i> factor from Wilson plot (Å ²)	26.9
Refinement statistics	
Resolution range (Å)	25.0–1.95
No. of reflections used for <i>R</i> _{free} calculation	39334/1971
<i>R</i> _{work} / <i>R</i> _{free} (%)	20.5/25.5
No. of atoms	
Protein	3326
Ligands	12
Solvent	310
<i>B</i> factors (Å ²)	
Protein	24.8
V _H	18.4
C _H	34.6
V _L	20.6
C _L	26.1
Ligands	19.1
Solvent	27.8
Root-mean-square deviations	
Bond lengths (Å)	0.01
Bond angles (°)	1.12
Ramachandran plot, residues in	
Most favoured regions	427 [96.8%]
Favoured regions	20 [3.2%]
Disallowed regions	0

(Clontech, USA). The eluted fraction was desalted against 50 mM sodium phosphate buffer pH 7.4 and separated by anion-exchange chromatography on a Mono Q column (Sigma) with salt-gradient elution (0–1 M NaCl in 50 mM sodium phosphate buffer pH 7.4). Fractions corresponding to Fabs were then purified on a Superdex 75 column (GE Healthcare, United States) equilibrated with 50 mM sodium phosphate buffer or 50 mM Tris–HCl buffer pH 7.4. The purity and identity of the eluted Fabs were tested by 12% SDS–PAGE with Coomassie staining and Western blot analysis. Horseradish peroxidase-conjugated anti-FLAG and anti-human light chain Abs (Sigma, USA) were used for detecting HC_H and C_L, respectively.

2.2. Crystallization and data collection

Crystals of FabA17 λ were grown using the hanging-drop vapour-diffusion method by mixing equal volumes of protein (7 mg ml^{−1} in 50 mM Tris–HCl buffer pH 7.4) and precipitant solution [0.25 M ammonium sulfate and 20% (w/v) polyethylene glycol 5000 monomethyl ether in 0.1 M 2-(*N*-morpholino)ethanesulfonic acid (MES) pH 6.5]. Rod-shaped crystals of approximately 0.4 × 0.1 × 0.1 mm in size were

¹ Supporting information has been deposited in the IUCr electronic archive (Reference: WD5216).

obtained after 3–4 d and X-ray data were collected on EMBL beamline P14 at the PETRA III storage ring (DESY, Hamburg, Germany) at a wavelength of 1.2234 Å using a MAR CCD 225 mm detector. The data were collected at a cryogenic temperature of 100 K, and the mother-liquor solution supplemented with 20%(v/v) PEG 400 was used as a cryoprotectant. Images of 0.25° oscillation were collected over a total rotation of 85° using 2 s exposure per image. The diffraction data were indexed and integrated with *XDS* (Kabsch, 2010) and scaled using *SCALA* (Evans, 2006). The values of $I/\sigma(I)$ and $CC_{1/2}$ (Karplus & Diederichs, 2012) were used as a guide to determine the resolution cutoff (Table 1).

2.3. Structure solution and refinement

The A17λ structure was solved by molecular replacement using *MOLREP* (Vagin & Teplyakov, 2010) with the heavy chain of the FabA17κ structure (PDB entry 2xza; Smirnov *et al.*, 2011) as a search model. Attempts to use the whole Fab structure as a model were unsuccessful, probably owing to the difference in the overall shape of the molecule.

The partial structure solution was followed by location of the V_L domain, which is identical in the λ and κ variants, and building of the rest of the Fab molecule was achieved using the *ARP/wARP* program (Langer *et al.*, 2008). A β-sheet of the C_L domain could not be built automatically and was added using several manual interventions with *Coot* (Emsley & Cowtan, 2004) and *PHENIX* (Afonine *et al.*, 2012), including simulated annealing. After completion of model building, refinement was carried out with *PHENIX* and *REFMAC5* (Murshudov *et al.*, 2011).

Solvent molecules were located automatically using *PHENIX* and were confirmed by visual inspection; all of them were well defined in density. All located water molecules were refined with unit occupancy. The final model consisted of one Fab molecule (Fig. 2) with 445 residues and 310 water molecules. The positions of two N-terminal residues of the light chain could not be located in the electron density. Close to the active centre, there was a well resolved residual density for a MES molecule that was present in the crystallization condition and refined with occupancy value of 0.8 (Fig. 3). A

stereochemical analysis of the structure using *PROCHECK* (Laskowski *et al.*, 1993) showed that 96.8% of the residues were in the most favoured regions of the Ramachandran plot and 3.2% were in favoured regions. The data were nominally collected to 1.89 Å resolution, but during processing the resolution was reduced to 1.95 Å. This moderate data truncation slightly improved the regions of poor electron density as well as the refinement statistics. The refinement was deemed to have converged at an *R* factor of 20.5% and an R_{free} of 25.5%. Data-collection and refinement statistics are presented in Table 1.




Figure 2

(a) The overall structure of the A17λ antibody. Heavy (V_H/C_{H1}) and light chains are shown in magenta and cyan, respectively. (b) The A17λ structure coloured according to the C^α atomic displacement parameters (ADP), with a colour transition from blue to red indicating increasing ADP values.




Figure 3

(a) $2F_o - F_c$ electron-density map contoured at the 1.5σ level above the mean ($0.4 \text{ e } \text{\AA}^{-3}$) showing the MES molecule, water 147 and the catalytic Tyr-L36. Heavy and light chains are shown in magenta and cyan, respectively. (b) An extended hydrogen-bonding pattern involving the MES molecule and five intact water molecules located close to the A17λ active centre (red dashed lines).

To check whether different search models or algorithms could affect the results of structure solution by molecular replacement, we also tried to use as search models individual domains from the A17 κ structure or other reported Ab structures that share high homology with A17 λ (e.g. PDB entries 3mly and 4evn; Jiang *et al.*, 2010; Lingwood *et al.*, 2012). Thus, solving the A17 κ structure with *MOLREP*, we first located the V_H domain using the V_H domain of the 2xza or the 3mly structure as a model and then the C_{H1} domain of the same structures. Thereafter, the V_L and C_L domains were located using as models the homologous domains from the 2xza and 4evn structures, respectively. Similar results were obtained by first locating the domains of the light chain and then those of the heavy chain or first the two variable domains and then the constant domains of the Ab. By carrying out molecular replacement with *Phaser* (McCoy *et al.*, 2007), it was also possible to locate the four domains of the Fab molecule by using individual domains of 2xza or 3mly for V_H and C_{H1} and of 4evn for V_L and C_L as search ensembles. The same results were also obtained by altering the order of the search ensembles. Finally, using the *BALBES* pipeline (Long *et al.*, 2008) it was possible to individually locate the V_H, C_{H1} and V_L domains of A17 λ and finally to use *ARP/wARP* to build most of the C_L domain. All of the solutions were very similar, with r.m.s.d. values of less than 1 Å for C $^{\alpha}$ atoms after rigid-body refinement.

2.4. Molecular-dynamics simulation

The GPU-accelerated *GROMACS* 4.6.3 software package (Pronk *et al.*, 2013) was used for the simulation and analysis of MD trajectories using the Amber ff99SB-ILDN force field (Lindorff-Larsen *et al.*, 2010). Explicit solvent simulations were performed at a temperature of 300 K with a time constant for coupling of 0.1 ps under the control of a velocity rescaling thermostat and isotropic constant-pressure boundary conditions under the control of the Berendsen algorithm of pressure coupling with a time constant of 5 ps and application of the particle mesh Ewald method for electrostatic interactions (PME). A triclinic box of TIP3P water molecules was added around the protein to a depth of 20 Å on each side of the solute. Charges were neutralized by the addition of chloride ions. Additional NaCl was added to the systems to a final concentration of 0.14 M. In each of the simulations, there were two temperature-coupling groups, the first consisting of protein and the second consisting of water with Na⁺ and Cl[−] ions. The time step for integration in all simulations was 2 fs. Coordinates were written to output as a trajectory file every 10 ps and the total time of simulation was 250 ns. All simulations were performed on a Lomonosov supercomputer provided by the SRCC of Moscow State University. Analysis of the trajectories was also performed using the *GROMACS* 4.6 software package.

2.5. Evaluation of kinetic and thermodynamic parameters for the reactibody reactions

Kinetic measurements were made as described by Reshetnyak *et al.* (2007) and Smirnov *et al.* (2011). Briefly, reactions

of FabA17 λ and FabA17 κ (3–32 μ M) with phosphonate X or paraoxon (Figs. 1*a* and 1*b*) over a concentration range of 10–500 μ M were carried out in 0.1 M sodium phosphate buffer pH 7.4 at different temperatures. Reaction rates were determined from the changes in absorbance at 405 nm owing to *p*-nitrophenol formation, and the rate constants were calculated using a *p*-nitrophenol extinction coefficient ϵ of 12 300 M^{−1} cm^{−1}. Active Ab concentrations were extrapolated from the $A_{\max}$ at 405 nm in the presence of excess phosphonate X. Modifications of rate constants k_1 were estimated by Kitz–Wilson analysis (for details, see Supporting Information §S1).

Stopped-flow measurements with fluorescence detection were made using an SX.18MV stopped-flow spectrometer (Applied Photophysics, England). All experiments were carried out in 20 mM sodium phosphate buffer pH 7.4 with 150 mM NaCl at different temperatures (280–293 K). The Trp fluorescence was excited at 290 nm and monitored at >320 nm. Each trace in the diagrams is the average of no fewer than four individual recordings. The concentration of Fabs in all experiments was 10 μ M and the concentrations of phosphonate and paraoxon were varied from 5 to 300 μ M. Kinetic parameters were calculated as described by Smirnov *et al.* (2011) using the *DynaFit* software (Kuzmic, 1996) (for details, see Supporting Information §S1).

Thermodynamic parameters (rate constants k_2 and equilibrium constants K_d ; Supplementary Table S1) for the interaction of phosphonate X with A17 were determined.

2.6. Determination of denaturation temperature

The denaturation temperatures (T_d) of A17 κ and A17 λ were measured in a VP-DSC microcalorimeter (MicroCal, USA) in 0.5 ml cells at a heating rate of 1 K min^{−1} as described in Mitkevich *et al.* (2003). Test solutions contained 0.6–1.5 mg ml^{−1} protein in 50 mM sodium phosphate buffer pH 7.4. The accuracy of the measurements was ± 0.1 K. To analyze functions of excess heat capacity, the *Origin-DSC* program package was used.

2.7. Phage library selection for binding the single-chain antibody scFvA17

The random cyclic heptapeptide phage library CX₇C was used (Koivunen *et al.*, 1994). The solid-phase selection procedures were performed according to Yribarren *et al.* (2003), with some modifications (for details, see Supporting Information §S2). The pool of phage-bound peptides selected after each round was tested for specificity toward scFvA17 by means of phage ELISA (Supplementary Fig. S2). DNA fragments encoding the peptides from 20 clones randomly taken after the fifth round were amplified by PCR and sequenced. As a result of amino-acid sequence alignment, two consensus sequences were identified: CRNPWGLTC (pep50) and CPNPWGLLC (pep54).

2.8. Peptide synthesis

The peptides were synthesized by standard solid-phase N α -Fmoc chemistry (for details, see Supporting Information

§S3). Two selected peptides were obtained in cyclic (50C or 54C) and linear (50L or 54L) forms, each consisting of 18 amino acids. The two residues at the N-terminus belonged to the bacteriophage pIII protein and were followed by a peptide sequence flanked by two cysteines. Lysine in the C-terminal part (GAAGAEEK), which is also found in the bacteriophage pIII protein, was conjugated with a biotin molecule. The final sequences of the peptides were as follows: $\text{NH}_2\text{-GACRNP-WGLTCGAAGAEEK(Biot)NH}_2$ (50) and $\text{NH}_2\text{-GACPNPW-GLLCGAAGAEEK(Biot)NH}_2$ (54).

2.9. Surface plasmon resonance (SPR) analysis

The surface plasmon resonance experiments were performed using a Biacore T200 system (GE Healthcare) equipped with a research-grade SA sensor chip. Chemically synthesized peptides (oxidized pep50C and pep54C, reduced pep50L and pep54L and a control peptide) were immobilized according to the manufacturer's protocol. Flow cell 1 was left blank as a reference surface. To collect kinetic binding data, A17 κ , A17 λ and control Abs were injected at a range of concentrations into the four flow cells at a flow rate of $10\ \mu\text{l min}^{-1}$ at 298 K. Ab-peptide association and dissociation were each monitored for 300 s. The surfaces were regenerated by a 100 s injection of 100 mM glycine-HCl pH 2.0. Data were collected at a rate of 1 Hz and fitted with a 1:1 binding model using the affinity-analysis option available within the *BIA-evaluation* software.

3. Results and discussion

3.1. Molecular organization of the A17 reactibody

Organophosphate-metabolizing A17scFv with variable domains corresponding to IGHV4-b*/IGLV1-51* germline genes was selected from a human semisynthetic Ab variable

fragment library using a covalent capture selection strategy (Reshetnyak *et al.*, 2007). To express full-length A17 reactibody in CHO cells, we used vectors permitting the production of a corresponding Ab with human constant domains of subclass IgG1/ κ (Smirnov *et al.*, 2011). Some differences were observed in the catalytic efficiency of full-length A17 or its Fab fragment compared with the parent scFv molecule (Zakharov *et al.*, 2011). On one hand, these differences could result from structural stabilization of the active centre owing to the presence of additional constant domains. Crystallographic studies show that there is a close association between V_L and V_H and between C_L and C_{H1} in the Fab (Padlan, 1994). Typically, Fv shares similar antigen-binding properties with Fab. However, the relative orientation of V_L and V_H in Fv is obviously not necessarily the same as in the Fab because the stabilizing effect of the $C_L\text{-}C_{H1}$ module (observed in Fab) is absent in Fv (Narciso *et al.*, 2011). On the other hand, the full-length A17 reactibody contained the artificial light chain with the λV_L domain fused to κC_L through the κ switch region (Fig. 1c) and this non-native domain could also affect the properties of Ab.

To solve this question, the natural λ light chain was constructed (Fig. 1c) and recombinant FabA17 containing a κ or λ light-chain constant region was produced in the methylo-trophic yeast *P. pastoris*.

3.2. Structure of the A17 λ Fab reactibody and its comparison with the A17 κ variant

3.2.1. Quality of the final model. The A17 λ crystals belonged to the tetragonal space group $P4_12_12$ and the model was refined to an R factor and R_{free} of 20.5 and 25.5%, respectively. The results showed that the asymmetric unit of the crystal contained one Fab molecule and four domains (V_L , C_L , V_H and C_{H1}) with the canonical β -sandwich immunoglobulin fold (Fig. 2). The final model comprises residues




Figure 4

(a) Interdomain interactions between the CDR loops of A17 λ and interactions involving catalytic Tyr-L37. Protein residues involved in these interactions are shown in ball-and-stick representation, water molecules are shown as spheres and hydrogen-bond interactions are shown as blue dashed lines. Here and in (b) and (c), heavy and light chains are shown in magenta and cyan, respectively. Tyr-L33 and Ser-L35 belong to L-CDR1, Asp-L51 to L-CDR2, Trp-L92 and Leu-L96 to L-CDR3, Tyr-H53 to H-CDR2, and Ser-H103, His-H104 and Asn-H105 to H-CDR3. (b) $2F_o - F_c$ electron-density map contoured at the 2σ level ($0.5\ \text{e}\ \text{\AA}^{-3}$) above the mean for the CDR loop region of A17 λ . (c) $2F_o - F_c$ electron-density map contoured at the 2σ level ($0.5\ \text{e}\ \text{\AA}^{-3}$) above the mean for the CDR loop region of A17 κ .

1–231 of the heavy chain and 3–216 of the light chain. Most of the structure, including the CDR regions, shows well defined electron density, except for the loops H 136–138, H 160–164 and L 170–173 (sequential numbering; for numbering according to Kabat, see Fig. 1c).

3.2.2. Comparison of the A17 λ and A17 κ structures. As calculated by the *PISA* program (Krissinel & Henrick, 2007), the interface area between the heavy and light chains in A17 λ is 1785 Å² and there are 18 hydrogen bonds, one salt bridge and one disulfide bond (Supplementary Table S2). This interface is comparable to others reported for Fab structures, but is more extended than that in the A17 κ structure (PDB entry 2xza; 1527 Å² with 12 hydrogen bonds and one salt bridge).

An important feature of the A17 λ structure and the key difference between the two variants is a large interface between the two variable domains of the Fab molecule, where interactions take place between the CDR loops located close to the A17 λ active centre, as well as Tyr-H53 from H-CDR2 (Fig. 4a). They include strong direct interactions between residues of the H-CDR3 loop with L-CDR1 and L-CDR2, between H-CDR2 and L-CDR3 (Supplementary Table S2), as well as contacts *via* water molecules and a bound MES molecule. These interactions result in the displacement of

these CDR loops, apart from H-CDR2, as follows from their structural alignment with the A17 κ structure (r.m.s.d. of 2.4 Å for C α atoms using *LSQKAB*; Kabsch *et al.*, 1976), and in the formation of a fairly rigid ensemble by the two variable domains, unlike in A17 κ , where these domains do not interact directly. In contrast, the H-CDR1 loop (which does not take part in this interface) and the H-CDR2 loop, which lies farther away from the active centre (similar to H-CDR1), are well aligned in the two structures (r.m.s.d. of 0.9 Å using *LSQKAB*). The presence of a large interdomain interface in A17 λ appears to provide stabilization of the CDR loops, as can be deduced from a comparison of their atomic displacement parameters (ADPs). Although the average ADP value for all protein atoms in the A17 λ structure is higher than in A17 κ (25.1 *versus* 21.5 Å²), the ADPs of the A17 λ CDR loops are much lower (17.0 *versus* 25.4 Å²) (Supplementary Table S3). Furthermore, the electron density in this region is very well defined (Fig. 4b), in contrast to the A17 κ structure, in which the electron density of the CDR loops is relatively poor (Fig. 4c). Comparison of the normalized ADP for residues of CDR loops for A17 κ (PDB entry 2xza), phosphorylated A17 κ (PDB entry 2xzc) and A17 λ (PDB entry 3z14) demonstrated that the ADP values for all CDR loops are generally higher for the two A17 κ structures compared with A17 λ , with no




Figure 5
(a) Superposition of the A17 λ and A17 κ variable domains. A17 λ CDR loops are shown in magenta and A17 κ CDR loops are shown in blue. The flip of the Trp-L92 side chain is indicated. (b) The flipping of Trp-L92 provides the enlargement of the hydrophobic pocket surface (Trp-L92–Phe-L100) and the formation of a kind of lid above the cavity entrance. The light chain of A17 κ is shown in cyan and the heavy chain is shown in brown; the light chain of A17 λ is shown in green and the heavy chain is shown in magenta.

considerable dependence on the crystal contacts taking place in this loop (Supplementary Table S4 and Fig. S3). This in turn means that the active centre of the A17 λ variant is more rigid than that of A17 κ .

The reported A17 λ structure is characterized by marked differences in the ADPs between the variable and constant domains of the chains. The average ADPs for all of the protein atoms in the V_H and V_L domains are 18.4 and 20.6 Å², compared with 34.6 and 26.1 Å² in the C_{H1} and C_L domains, respectively (Fig. 2*b*). This is presumably owing to an extended interaction between the variable domains, with the constant domains being more mobile. In contrast, the A17 κ variant shows an even distribution of ADP values, which average 19.2 and 19.2 Å² for V_H and V_L and 17.3 and 19.3 Å² for C_{H1} and C_L, respectively. Certain differences in the ADPs between the variable and constant domains (with a slightly higher mobility for the constant domains) are not rare. In a survey of 200 high-resolution structures of unliganded Fab molecules deposited in the PDB, we found that the average ADPs for the C α atoms of variable domains are almost identical, 29 Å² for V_H and 28 Å² for V_L, with this parameter being slightly higher for the constant domains: 31 Å² for both C_{H1} and C_L (Supplementary Fig. S4). Obviously, the corresponding differences in the case of A17 λ are much greater.

The active centre of A17 λ structurally deviates from that of A17 κ . The major difference is that the upper part of the A17 λ active centre is shifted away from the light chain. This shifting of the L-CDR3 loop, which is mainly caused by the strong interaction between Tyr-H53 and Leu-L96, leads to the displacement of Trp-L92 by about 4 Å, its flipping and rotation

(Fig. 5). This displacement of L-CDR3, and Trp-L92 in particular, which is probably facilitated by the crystal contacts or the presence of the MES molecule (Fig. 3*b*), results in the enlargement of the hydrophobic pocket surface and the formation of a lid above the cavity entrance (Fig. 5*b*). To estimate the level of involvement of the crystal contacts in the active-centre architecture, we performed an MD simulation of the behaviour of A17 κ and A17 λ in a dilute solution environment and without any neighbouring molecules, including MES for A17 λ . In A17 κ , displacement of the symmetry-related molecules by water leads to nonsignificant relaxation of the structure (protein backbone r.m.s.d. of 1.2 and 1.3 Å for the heavy and light chains, respectively). The same estimation performed for A17 λ revealed noticeable changes in the structure (protein backbone r.m.s.d. of 2.2 and 2.7 Å for the heavy and light chains, respectively) and movement of L-CDR3 and H-CDR3 followed by hydrogen-bond formation between the side chain of Trp-L92 and the main chain of Asn-H105 (Supplementary Fig. S5). It should be noted that this is not observed in the case of the A17 κ MD structure during the entire simulation time; therefore, the rearrangement of A17 λ mainly occurred owing to the removal of the MES molecule from the active site. The observations described above allow us to suggest that crystal contacts do not play a significant role in the structure of the A17 κ active centre, but the impact of packing interactions for A17 λ cannot be ruled out.

In the reported A17 λ structure, the catalytic Tyr-L37 forms a hydrogen bond to Trp-H109, while a water molecule bridges it to Ser-L35 and Asn-H105, thereby forming a rigid entity (Fig. 4*a*). In A17 κ , Tyr-L37 does not directly interact with

neighbouring residues but forms an extended hydrogen-bonding network through solvent molecules (Smirnov *et al.*, 2011). In the presence of co-crystallized MES, Tyr-H34 in A17 λ is not directed towards Tyr-L37 but turns to form a hydrogen bond with Ser-H51. The positions of Tyr-L33 and Asn-H105 deviate from those in A17 κ owing to a hydrogen-bonding pattern that is formed *via* one MES and five water molecules located close to the active centre. We think that this fairly extended hydrogen bonding (Fig. 3*b*) stabilizes the protein and at the same time prevents the modification of A17 λ by phosphonate X in crystals containing MES, in contrast to the crystal structure of A17 κ , in which this modification is possible.

3.2.3. Stability of the antibody variants. To determine whether this extended hydrogen-bonding pattern at the active centre of





Figure 6
Structural superposition of the A17 κ (blue) and A17 λ (magenta) light chains on the V_L domain. The Gly-L110 insertion in A17 λ accounts for the change in the V_L–C_L orientation compared with that in A17 κ .

Table 2Kinetic parameters for the interaction of phosphonate X with κ and λ variants of A17.

	Phosphonate X		k_2/K_d ($M^{-1} \text{ min}^{-1}$)	ΔG (kcal mol^{-1})	ΔH (kcal mol^{-1})	ΔS ($\text{cal mol}^{-1} \text{ K}^{-1}$)	$E_a^\dagger$ (kcal mol^{-1})	Paraoxon
	k_2 (min^{-1})	K_d (M)						k_2/K_d ($M^{-1} \text{ min}^{-1}$)
A17 κ	0.24 ± 0.03	$(120 \pm 15) \times 10^{-6}$	2000 ± 500	-6.5 ± 0.1	-4.1 ± 0.3	4.0 ± 1.2	12.5 ± 1.3	1.2 ± 0.5
A17 λ	0.28 ± 0.02	$(130 \pm 15) \times 10^{-6}$	2200 ± 400	-6.5 ± 0.1	-3.0 ± 0.4	7.6 ± 1.8	11.4 ± 0.5	1.6 ± 0.6

 $^\dagger E_a$ is the activation-energy parameter.**Figure 7**
Elbow angles in A17 reactibody variants. A17 κ -P is a phosphonylated variant.

A17 λ and interdomain interaction stabilize the Fab molecule, we measured the denaturation temperatures (T_d) of κ and λ Fabs and their phosphonylated forms. The denaturation curves for the proteins had only one peak, indicating that the Fab molecules formed a single structural ensemble in all variants. The T_d values of the two λ variants were higher than those of the κ variants (339.8 *versus* 335.5 K for unmodified proteins and 347.1 *versus* 344.9 K for phosphonylated proteins, respectively).

These results indicate that the $\kappa \rightarrow \lambda$ switch leads to stabilization of the antibody molecule, possibly owing to the aforementioned interaction between the CDR loops. Furthermore, higher T_d values in the phosphonylated variants compared with the unmodified antibodies indicate that the phosphonylation stabilizes the antibody molecule.

3.2.4. Structural alignment. Structure-based sequence alignment of λ and κ light chains revealed a high similarity between them. The variable domains of the light chain are identical (Supplementary Fig. S6), while the C_L domains and J regions connecting the V_L and C_L domains show only 42% sequence identity and 83% secondary-structure matching as calculated by the *PDBFold* algorithm (Krissinel & Henrick, 2004). Alignment of the C^α atoms of the two structures using the *LSQKAB* algorithm resulted in r.m.s.d. estimates of 1.1 Å for the heavy chains and 4.1 Å for the light chains. Such a large structural deviation between κ and λ chains mainly appears to be owing to the J segment, especially to the Gly-L110 insertion

in the λ variant, which changes the orientation of the C_L domain relative to V_L so that it forms a rotation angle of 29° with the latter (Fig. 6). In addition to the Gly-L110 insertion, the substitution of the positively charged Arg-L111 in A17 κ by Gln-L111 in A17 λ also appears to play a role in differentiation between the two light chains, since Gln-L111 strongly interacts with Tyr-L143, Val-L108 and Glu-L84. In A17 κ , Arg-L111 is turned away from Tyr-L143, possibly because of steric effects, and forms a hydrogen bond with Asp-L172.

3.2.5. Comparison of the elbow angles. The elbow angle of the FabA17 λ molecule is 126° .

This value is at the lower limit of the range previously recorded in Fab molecules ($125\text{--}225^\circ$) and differs considerably from that characteristic of λ chain-type Fabs, which tend to adopt large elbow angles (Stanfield, Zemla *et al.*, 2006). Structural comparisons of A17 λ with A17 κ (PDB entry 2xza) and A17 κ phosphonylated by phosphonate X (PDB entry 2xzc) allowed us to conclude that neither the $\kappa \rightarrow \lambda$ light-chain switch nor phosphonylation have any significant effect on the elbow angle (Fig. 7). As for the overall structure of the two constant domains (C_{H1} and C_L) in the Fab molecule, the change in the C_L domain of A17 λ resulted in some differences in its orientation relative to C_{H1} , as follows from the comparison of the twist/tilt angles between the two domains ($176/97^\circ$ in A17 λ *versus* $184/104^\circ$ in A17 κ) and in the alignment of these modules in the two structures (r.m.s.d. of 3.2 Å when aligned using the *LSQKAB* algorithm).

3.3. Functional characteristics of FabA17 reactibody variants with κ and λ light chains

The newly obtained FabA17 λ is a fully functional reactibody with a reactivity comparable to that of the κ variant. Comparison between A17 reactibodies with κ and λ light chains with respect to the steady-state kinetic parameters of their interaction with the phosphonate X molecule showed that K_d and k_2 for A17 λ were similar to those for A17 κ (Table 2). The slight difference in K_d indicates a certain divergence

Table 3

Stopped-flow kinetic parameters of the interaction of phosphonate X with κ and λ variants of A17.

The errors indicated are ± 1 SD.

	k_1 ($M^{-1} s^{-1}$)	k_{-1} (s^{-1})	k_2 (s^{-1})	k_{-2} (s^{-1})	k_{obs1}	k_{obs2}
A17 κ	$(6.6 \pm 0.5) \times 10^{-6}$	460 ± 35	46 ± 7	150 ± 20	530 ± 90	130 ± 30
A17 λ	$(17.5 \pm 0.8) \times 10^{-6}$	480 ± 35	65 ± 10	90 ± 12	580 ± 90	80 ± 20

Table 4

BiaCore affinity constants for interactions of A17 κ and A17 λ reactibodies with linear (50L and 54L) and cyclic (50C and 54C) peptides.

	$K_d(50L)$ ($10^6 M$)	$K_d(54L)$ ($10^6 M$)	$K_d(50C)$ ($10^6 M$)	$K_d(54C)$ ($10^6 M$)
A17 κ	1.3 ± 0.1	25.0 ± 5.0	0.9 ± 0.1	25.7 ± 0.5
A17 λ	2.3 ± 0.3	18.0 ± 4.0	2.20 ± 0.08	4.8 ± 0.6

between these variants at the first (rapid) stage of ligand binding (see Scheme 1 in Supporting Information S§1).

To reveal the details of the reaction process, thermodynamic and pre-steady-state kinetic parameters were evaluated for A17 κ and A17 λ .

Thermodynamic parameters were calculated from the values of the K_d and k_2 constants as a function of temperature (Supplementary Table S1 and Fig. S7). The energies of A17 κ and A17 λ modification by phosphonate X are comparable in terms of enthalpy and free energy; however, the reaction of A17 λ with phosphonate X is more entropically favourable (Table 2).

The pre-steady-state kinetic analysis of interaction of A17 λ with phosphonate X revealed two noncovalent binding stages, with the first rapid stage corresponding to the bimolecular interaction of the reactibody with the phosphonate ligand and the second stage involving induced-fit conformational changes of the reactibody. This is in agreement with previously reported data on the A17 κ reactibody (Smirnov *et al.*, 2011). Comparison of kinetic parameters for A17 κ and A17 λ shows that the induced-fit stage is more rapid in the κ variant (Table 3). This may be owing to the less rigid structure of A17 κ , with the entrance to its active centre being wider than in A17 λ , where it is significantly narrowed because of interactions between the CDR loops. These conformational peculiarities provide more rapid and precise fitting of this reactibody to the phosphonate molecule.

An X-ray analysis of both A17 variants has shown that they have a well developed, deep active centre with the nucleophilic Tyr-L37 at the bottom of the cavity (15 Å from the surface of the molecule). A similar architecture of the active centre with Tyr-L37 has previously been described for the mouse catalytic Ab 13G5 (Heine *et al.*, 1998). This part of the Ab molecule is highly conserved and belongs to its structural core, which usually does not interact with antigens (Narciso *et al.*, 2012). This fact may account for the absence of marked differences between A17 κ and A17 λ in the kinetic parameters of their interaction with organophosphates. The observed structural divergence of CDRs loops can lead to changes in the antigen-binding properties of Ab molecules. Since A17 was selected as a biocatalyst using artificial chemical

substrates, it was relevant to find out whether there is an epitope to which A17 is naturally intended to bind. As we failed to detect such an antigen among nucleic acids, lipids and polysaccharides (data not shown), we focused on epitopes of a protein nature. To address the question of the antigen specificity of

A17 κ and A17 λ , we used a combinatorial approach. 'Epitope mapping' was performed by screening a phage-displayed cyclic heptapeptide library. To facilitate this procedure, scFvA17 was used for peptide-epitope selection. The scFv molecule consists of only the variable domains of the light and heavy chains connected through an (SG₄)₂SGGSAL linker; therefore, any effect from the constant domains was excluded. The scFvA17 proved to specifically bind two phage-displayed peptides, pep50 and pep54. It was found that the recombinant Fab reactibodies were also capable of binding the selected phage-displayed peptides pep50 and pep54, retaining this capacity after modification by phosphonate X (Supplementary Fig. S8). However, phosphorylation of the Fabs reduced the level of binding (Supplementary Fig. S8a), whereas such a modification of scFv significantly enhanced the ELISA signals (Supplementary Fig. S8b). The phosphonate ligand is completely buried in the active centre, being inaccessible for direct interaction with the peptides. Therefore, we suggest that covalent modification may have an indirect effect on the interaction of the antibody with the peptides.

To make a more accurate comparison of antigen-binding properties between the two A17 variants, we performed SPR analysis of reactibody binding with synthetic cyclic (pep50C and pep54C) and linear (pep50L and pep54L) peptides.

The affinity parameters determined from the sensorgrams are shown in Table 4 and Supplementary Fig. S9. Both A17 κ and A17 λ proved to have high affinity for the pep50L and pep50C peptides. However, A17 κ was more active in binding either the linear or the cyclic form of pep50, which could be owing to its less rigid structure. In the case of pep54C, A17 λ was more active than A17 κ . A probable explanation is that the cyclic structure of pep54C fits better to the rigid A17 λ antigen-binding site.

4. Conclusions

Determination of the structure of the A17 λ reactibody variant and its comparison with the previously reported structure of A17 κ has provided an insight into changes in the structure–function relationship upon the $\kappa \rightarrow \lambda$ switch. It should be emphasized that the results presented above are based on direct comparison between the two light-chain variants of the same antibody A17, rather than on a statistical survey of structures reported for different antibodies. They show that an exchange of the light-chain constant domain produces an effect on the active-centre architecture, altering the overall shape of the light chain and consequently its orientation relative to the heavy chain. This alteration is also reflected in the interaction between the variable domains *via* their CDR

loops, which leads to deformation of the cavity entrance and makes the binding pocket of A17 λ different from that of A17 κ ; however, the impact of packing interactions cannot be formally ruled out. The elbow angle differs slightly between the two variants and is slightly reduced in A17 λ compared with A17 κ , in contrast to the data reported previously for antibodies with κ and λ light chains. As suggested previously (Stanfield, Zemla *et al.*, 2006), changes in elbow angles may simply serve to increase the flexibility of the Fab. Such changes could affect the reaction mechanism of the biocatalyst. Overall, the physicochemical (crystallographic, kinetic and thermodynamic) data and the results of artificial epitope mapping for both light-chain variants of A17 show that the replacement of the light-chain constant domain has an effect on the stability and antigen-binding properties of the reactibody, but not on its reactivity. In our opinion, the domain structure of an antibody molecule should be taken into account in the design of novel artificial biocatalysts.

This study, performed within the framework of RFBR–EMBL program ‘Structure–Function Interrelation in Artificial Enzymes’ (project no. 12-04-92428), was supported by the Skolkovo program, RFBR grants (projects nos. 11-04-02016-a, 12-04-00474-a, 12-04-01609-a, 12-04-33258, 13-04-40277, 14-04-31223, 14-04-31207, 13-04-40279-N KOMFI and 13-04-40280-N KOMFI); programs of the Presidium of Russian Academy of Sciences ‘Fundamental Sciences for Medicine’, ‘Molecular and Cellular Biology’ (AAM, OSF, AG) and ‘Nanotechnologies and Nanomaterials’ (no. 24); the Scientific School Support Program ‘Chemical Basis of Biocatalysis’ (project no. 2046.2014.4); the Ministry of Education and Science of the Russian Federation (project no. 8283); grant no. 4238 from PICS Centre National de la Recherche Scientifique France–Russia. Computer resources were provided by the Research Computing Center of Moscow State University. The supercomputer ‘Lomonosov’ was used for all modelling studies. The authors acknowledge the access to the macromolecular crystallography beamline P14 (EMBL/DESY, Hamburg) and are grateful to N. A. Gorgolyuk for his help in preparing the manuscript.

References

- Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). *Acta Cryst.* **D68**, 352–367.
- Eddleston, M., Buckley, N. A., Eyer, P. & Dawson, A. H. (2008). *Lancet*, **371**, 597–607.
- Ekiert, D. C. *et al.* (2012). *Nature (London)*, **489**, 526–532.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
- Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
- Gabibov, A. G. *et al.* (2011). *FASEB J.* **25**, 4211–4221.
- Golinelli-Pimpaneau, B., Goncalves, O., Dintinger, T., Blanchard, D., Knossow, M. & Tellier, C. (2000). *Proc. Natl Acad. Sci. USA*, **97**, 9892–9895.
- Guddat, L. W., Shan, L., Anchin, J. M., Linthicum, D. S. & Edmundson, A. B. (1994). *J. Mol. Biol.* **236**, 247–274.
- Guddat, L. W., Shan, L., Fan, Z.-C., Andersen, K. N., Rosauer, R., Linthicum, D. S. & Edmundson, A. B. (1995). *FASEB J.* **9**, 101–106.
- Guenaga, J. & Wyatt, R. T. (2012). *PLoS Pathog.* **8**, e1002806.
- Heine, A., Stura, E. A., Yli-Kauhaluoma, J. T., Gao, C., Deng, Q., Beno, B. R., Houk, K. N., Janda, K. D. & Wilson, I. A. (1998). *Science*, **279**, 1934–1940.
- Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M. & Palm, W. (1976). *Nature (London)*, **264**, 415–420.
- Jiang, X., Burke, V., Totrov, M., Williams, C., Cardozo, T., Gorny, M. K., Zolla-Pazner, S. & Kong, X.-P. (2010). *Nature Struct. Mol. Biol.* **17**, 955–961.
- Kabsch, W. (2010). *Acta Cryst.* **D66**, 133–144.
- Kabsch, W., Kabsch, H. & Eisenberg, D. (1976). *J. Mol. Biol.* **100**, 283–291.
- Kaneko, E. & Niwa, R. (2011). *BioDrugs*, **25**, 1–11.
- Karplus, P. A. & Diederichs, K. (2012). *Science*, **336**, 1030–1033.
- Klohn, P. C., Wuellner, U., Zizlsperger, N., Zhou, Y., Tavares, D., Berger, S., Zettlitz, K. A., Proetzel, G., Yong, M., Begent, R. H. & Reichert, J. M. (2013). *MAbs*, **5**, 178–201.
- Koivunen, E., Wang, B. & Ruoslahti, E. (1994). *J. Cell Biol.* **124**, 373–380.
- Krissinel, E. & Henrick, K. (2004). *Acta Cryst.* **D60**, 2256–2268.
- Krissinel, E. & Henrick, K. (2007). *J. Mol. Biol.* **372**, 774–797.
- Kuzmic, P. (1996). *Anal. Biochem.* **237**, 260–273.
- Landolfi, N. F., Thakur, A. B., Fu, H., Vásquez, M., Queen, C. & Tsurushita, N. (2001). *J. Immunol.* **166**, 1748–1754.
- Langer, G. G., Cohen, S. X., Perrakis, A. & Lamzin, V. S. (2008). *Nature Protoc.* **3**, 1171–1179.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). *J. Appl. Cryst.* **26**, 283–291.
- Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O. & Shaw, D. E. (2010). *Proteins*, **78**, 1950–1958.
- Lingwood, D., McTamney, P. M., Yassine, H. M., Whittle, J. R. R., Guo, X., Boyington, J. C., Wei, C.-J. & Nabel, G. J. (2012). *Nature (London)*, **489**, 566–570.
- Long, F., Vagin, A. A., Young, P. & Murshudov, G. N. (2008). *Acta Cryst.* **D64**, 125–132.
- Lu, Z.-J., Deng, S.-J., Huang, D.-G., He, Y., Lei, M., Zhou, L. & Jin, P. (2012). *World J. Biol. Chem.* **3**, 187–196.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Mitkevich, V. A., Schulga, A. A., Ermolyuk, Y. S., Lobachov, V. M., Chekhov, V. O., Yakovlev, G. I., Hartley, R. W., Pace, C. N., Kirpichnikov, M. P. & Makarov, A. A. (2003). *Biophys. Chem.* **105**, 383–390.
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). *Acta Cryst.* **D67**, 355–367.
- Narciso, J. E. T., Uy, I. D. C., Cabang, A. B., Chavez, J. F. C., Pablo, J. L. B., Padilla-Concepcion, G. P. & Padlan, E. A. (2011). *New Biotechnol.* **28**, 435–447.
- Narciso, J. E. T., Uy, I. D. C., Cabang, A. B., Chavez, J. F. C., Pablo, J. L. B., Padilla-Concepcion, G. P. & Padlan, E. A. (2012). *Philipp. Sci. Lett.* **5**, 63–89.
- Padlan, E. A. (1994). *Mol. Immunol.* **31**, 169–217.
- Parmley, S. F. & Smith, G. P. (1988). *Gene*, **73**, 305–318.
- Ponomarenko, N. A., Pillet, D., Paon, M., Vorobiev, I. I., Smirnov, I. V., Adenier, H., Avale, B., Kolesnikov, A. V., Kozyr, A. V., Thomas, D., Gabibov, A. G. & Friboulet, A. (2007). *Biochemistry*, **46**, 14598–14609.
- Privett, H. K., Kiss, G., Lee, T. M., Blomberg, R., Chica, R. A., Thomas, L. M., Hilvert, D., Houk, K. N. & Mayo, S. L. (2012). *Proc. Natl Acad. Sci. USA*, **109**, 3790–3795.
- Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B. & Lindahl, E. (2013). *Bioinformatics*, **29**, 845–854.
- Reshetnyak, A. V., Armentano, M. F., Ponomarenko, N. A., Vizzuso, D., Durova, O. M., Ziganshin, R., Serebryakova, M., Govorun, V., Gololobov, G., Morse, H. C. III, Friboulet, A., Makker, S. P., Gabibov, A. G. & Tramontano, A. (2007). *J. Am. Chem. Soc.* **129**, 16175–16182.

- Sapparapu, G., Planque, S., Mitsuda, Y., McLean, G., Nishiyama, Y. & Paul, S. (2012). *J. Biol. Chem.* **287**, 36096–36104.
- Smirnov, I. *et al.* (2011). *Proc. Natl Acad. Sci. USA*, **108**, 15954–15959.
- Sottriffer, C. A., Rode, B. M., Varga, J. M. & Liedl, K. R. (2000). *Biophys. J.* **79**, 614–628.
- Stanfield, R. L., Gorny, M. K., Zolla-Pazner, S. & Wilson, I. A. (2006). *J. Virol.* **80**, 6093–6105.
- Stanfield, R. L., Zemla, A., Wilson, I. A. & Rupp, B. (2006). *J. Mol. Biol.* **357**, 1566–1574.
- Turner, J. M., Larsen, N. A., Basran, A., Barbas, C. F. III, Bruce, N. C., Wilson, I. A. & Lerner, R. A. (2002). *Biochemistry*, **41**, 12297–12307.
- Vagin, A. & Teplyakov, A. (2010). *Acta Cryst.* **D66**, 22–25.
- Vincent, K. J. & Zurini, M. (2012). *Biotechnol. J.* **7**, 1444–1450.
- Yribarren, A. S., Thomas, D., Friboulet, A. & Avallé, B. (2003). *Eur. J. Biochem.* **270**, 2789–2795.
- Zakharov, A. V., Smirnov, I. V., Serebryakova, M. V., Dronina, M. A., Kaznacheeva, A. V., Kurkova, I. N., Belogurov, A. A., Friboulet, A., Ponomarenko, N. A., Gabibov, A. G. & Bobik, T. V. (2011). *Mol. Biol.* **45**, 74–81.
- Zheng, L., Goddard, J. P., Baumann, U. & Reymond, J. L. (2004). *J. Mol. Biol.* **341**, 807–814.